Dna X (SONM) Cash from Financing Activities (2018 - 2025)

Dna X's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• Quarterly Cash from Financing Activities rose 46.25% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.5 million (up 319.41% YoY) and the FY2025 annual result came in at $19.5 million, up 319.41% from the prior year.
• Cash from Financing Activities was $1.2 million for Q4 2025 at Dna X, down from $7.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $18.6 million in Q4 2021 and bottomed at -$37000.0 in Q1 2023.
• A 5-year average of $3.3 million and a median of $591000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 676200.0% — and 2023, when it tumbled 511.11%.
• Dna X's Cash from Financing Activities stood at $18.6 million in 2021, then tumbled by 100.19% to -$36000.0 in 2022, then fell by 2.78% to -$37000.0 in 2023, then soared by 2262.16% to $800000.0 in 2024, then surged by 46.25% to $1.2 million in 2025.
• Business Quant data shows SONM's Cash from Financing Activities at $1.2 million in Q4 2025, $7.2 million in Q3 2025, and $4.8 million in Q2 2025.